

# **COMMUNICABLE DISEASE REPORT**

## **Quarterly Report**

Volume 31, Number 3

December 2014

#### Healthcare-Associated Infections

In past issues of the Communicable Disease Report the focus has been on antibiotic-resistant organisms commonly reported from healthcare facilities including methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile* (CD) and the healthcare-associated infections attributed to these organisms. Healthcare-associated infections (HAIs) are infections acquired while receiving health care whether the individual is in a hospital, long-term care facility, ambulatory care, or at home. This report will highlight the surveillance reports for these organisms and will introduce other HAIs such as device associated infections.

#### **MRSA and CDI**

In NL, surveillance for MRSA and CD infections has been ongoing since 2009. Infection Prevention and Control (IPAC) Programs in each Regional Health Authority (RHA) have been instrumental in reporting these infections. More importantly, the IPAC Programs have been influential in highlighting the importance of preventing these infections. Strategies to address prevention include having a comprehensive hand hygiene program which incorporates hand hygiene education and audits of the hand hygiene practices of healthcare workers (HCWs). Hand hygiene is the single most important way to prevent infections in healthcare settings. In each hospital facility an emphasis has been placed on having hand hygiene access at the point-of-care. This would include having hand hygiene sinks or alcohol-based hand rubs readily available for use by HCWs, patients and visitors. Patients are encouraged to become partners in hand hygiene by being informed of the importance of practicing hand hygiene and by promoting hand hygiene to others.

Other IPAC activities include education on the importance of adhering to Routine Practices (RP) and Additional Precautions (AP) using the RPAP Tools set, surveillance activities which encompasses providing best practice guidelines on surveillance targets, providing feedback to HCWs on rates of infections and establishing dialogue with HCWs on preventative approaches. The results of the MRSA and CDI surveillance for acute care facilities in NL from January 01, 2010 to December 31, 2014 are provided in Figure 1 and Figure 2 respectively. The numerator is the number of infections for each acute care facility and the denominator is the total number of patient days for the facility in each RHA. In Figure 1, the MRSA rate in acute care facilities illustrates a notable decline in the rate over the five year.




Figure 1: Incidence rate of MRSA infections in acute care facilities, Newfoundland and Labrador, 2009 – 2014

*Clostridium difficile* infection (CDI) is recognized as the most frequent cause of outbreaks of infectious diarrhea in Canadian hospitals and long-term care facilities and has been independently associated with an increased risk of in-hospital death.<sup>1</sup> A comprehensive study in an Ottawa hospital reported one death for every ten patients acquiring CDI.<sup>2</sup> The incidence rate for CDI in Canadian hospitals declined to 5.1/100,000 patient care days in 2013 from a range of 5.8 - 6.7 reported between 2009-2012.<sup>3</sup> In NL, although a slight rise is shown in the CDI rate over the past five years (Figure 2), the provincial rate ranges from 1.4 - 2.1 for 2010 – 2014 thus remains below the Canadian average.




Figure 2: Incidence rate of *Clostridium difficile* infections in acute care facilities, Newfoundland and Labrador, 2009 – 2014

Note: A more sensitive test was used in the regions as follows. Eastern Health in September 2012, Western in December 2012, Central in October 2013, and Labrador-Grenfell in February 2013.

### **Device-related HAIs**

Devices commonly used in the treatment of patients both in acute care hospitals and long-term care facilities have been associated with HAIs including urinary catheters, central-lines and ventilators. Ventilator-associated pneumonia (VAP) is a leading cause of death for HAIs; it can also lead to increased ventilator days and increased length of stay for patients.<sup>4</sup> Central lines are often placed in patients requiring dialysis or intensive care. These lines have been associated with significant blood stream infections and death.<sup>5</sup> Catheter-associated urinary tract infections (CAUTIs) are the most common HAIs in hospitals and long-term care facilities worldwide.<sup>6,7</sup> In the United States it is estimated that the cost of CAUTIs is \$340-\$370 million per year.<sup>6</sup> Not only do these infections cause grief to the patients but they are also a cause for concern as they contribute to the emergence of antibiotic-resistant pathogens.

The Canadian Patient Safety Institute has partnered with Infection Prevention and Control Programs to emphasize the importance of preventing these patient safety incidents. Healthcare workers have been provided with care bundles which have a number of infection prevention strategies to reduce device-related HAIs. The implementation of these initiatives has been influential in decreasing infections related to these devices. Infection prevention and control experts are now encouraging patients to become more active in their safe and correct care. Patients or their loved ones can be involved in the following ways:

- Communicate your concerns Speak up and ask questions about your care. If you have devices (such as a urinary catheter) ask if it is still needed.
- Clean your hands Hand hygiene is the single most important way to prevent the transmission of infections in healthcare. Also ensure that healthcare workers and visitors clean their hands.
- Choose to be vaccinated The influenza and pneumococcal vaccines help prevent pneumonia.
- Get smart about antibiotics Ask questions about the antibiotics that you have been given; do you need them and are they the correct for you? Watch out for diarrhea. If you have three or more diarrhea episodes in 24 hours; tell your doctor.
- Know the signs of infections to watch for Redness, pain or drainage at an IV catheter site or surgery site may be an indication of infection. Tell your doctor if you have these symptoms.

and Waterborne and Waterborne Ca Ca Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy	ISEASE NAME		14											Newlo Lat	undlar orador	10
and Waterborne Bo Ca Ca Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy		TOTAL			EASTERN			CENTRAL			WESTERN			LABRADOR GRENFEL		
and Waterborne Bo Ca Ca Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy Cy		Dec	YTD 14	YTD 13	Dec	YTD 14	YTD 13	Dec	YTD 14	YTD 13	Dec	YTD 14	YTD 13	Dec	YTD 14	YTD 1
Bo Ca Ca Ca Cy Cy Gi Gi He Lis No Sa Sa Sa Sh Sh Sa Sh Ye Diseases fransmitted by Direct Contact Infl Route Infl Infl Infl Infl Infl Infl Infl	moebiasis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cry Cy Gia He Lis No Sa Sa Sh Sh Sh Ve Ve Ve Diseases Transmitted by Direct Contact and Respiratory Route Infi Infi Infi Infi Infi Infi Inv Inv	otulism	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cy Cy Gia He Lis No Sa Sa Sh Sh Ye Ve Ye Diseases Transmitted by Direct Contact and Respiratory Route Infi Infi Infi Infi Infi Infi Infi Infi	ampylobacteriosis	3	40	47	3	30	27	0	6	11	0	4	9	0	0	0
Cry Gia Lis Lis No Sa Sh Sh Ve Ve Ve Diseases Transmitted by Direct Contact and Respiratory Route Infl Infl Inv	ryptosporidiosis	0	4	3	0	0	0	0	0	0	0	3	3	0	1	0
Gia He Lis No Sa Sa Sh Sh Ve Ve Diseases Fransmitted by Direct Contact Infl Route Infl Infl Infl Infl Infl Infl Infl Infl	yclosporiasis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
He Lis No Sa Sh Sh Tyj Ve Ve Diseases Fransmitted by Direct Contact and Respiratory Route Infi Infi Infi Infi Infi Infi Infi Infi	ytomegalovirus	2	29	25	2	17	19	0	6	2	0	4	1	0	2	3
Lis No Sa Sh Tyj Ve Ye Diseases Fransmitted by Direct Contact and Respiratory Route Infi Infi Inv Inv Inv Inv	iardiasis	1	20	31	0	1	2	1	5	3	0	9	24	0	5	2
No Sa Sh Tyj Ve Ye Diseases Fransmitted by Direct Contact and Respiratory Route Infi Infi Infi Inv Inv	epatitis A	0	5	0	0	2	0	0	2	0	0	1	0	0	0	0
Sa Sh Tyj Ve Ye Diseases fransmitted by Direct Contact and Respiratory Route Infi Infi Infi Inv Inv Inv	isteriosis	0	1	1	0	0	1	0	0	0	0	1	0	0	0	0
Sh Typ Ve Ye Diseases Transmitted by Direct Contact and Respiratory Route Infl Infl Inv Inv Inv Inv Inv	orovirus Infection	10	41	88	2	4	38	0	16	26	8	21	21	0	0	3
Type Ve Ve Diseases Transmitted by Direct Contact and Respiratory Route Infi Infi Infi Inv Inv Inv	almonellosis	0	83	55	0	31	29	0	26	10	0	21	8	0	5	8
Ve Ve Diseases Transmitted by Direct Contact Infl Route Infl Infl Infl Infl Infl Inv Inv Inv	higellosis	0	2	3	0	1	3	0	0	0	0	0	0	0	1	0
Ye Diseases Fransmitted by Direct Contact And Respiratory Route Infi Infi Infi Infi Infi Infi Infi Infi	yphoid/Paratyphoid Fever	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ye Diseases Fransmitted by Direct Contact And Respiratory Route Infi Infi Infi Infi Infi Infi Infi Infi	erotoxigenic Escherichia coli	0	9	4	0	9	4	0	0	0	0	0	0	0	0	0
Transmitted by Direct Contact and Respiratory Route Infi Infi Infi Infi Infi Infi Infi Infi	ersiniosis	0	1	1	0	0	0	0	0	0	0	1	1	0	0	0
Transmitted by Direct Contact and Respiratory Route Infl Infl Inv Inv Inv	reutzfeldt-Jakob Disease (CJD)	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
Infl Respiratory Route Infl Infl Infl Inv Inv Inv	roup B Streptococcal Disease of Newborn	0	2	1	0	0	0	0	0	0	0	1	0	0	1	1
Route Infl Infl Infl Inv	fluenza Virus of a Novel Strain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Infl Inv Inv Inv Inv	fluenza A, Laboratory Confirmed	215	562	627	62	243	258	76	119	135	58	114	197	19	86	37
Inv Inv Inv Inv	fluenza B, Laboratory Confirmed	2	252	33	1	71	10	0	85	10	1	90	11	0	6	2
Inv Inv Inv Inv	vasive Group A Streptococcal Disease	1	10	9	0	6	3	0	0	1	1	4	3	0	0	2
Inv Inv	vasive Haemophilus Influenza non-type B	0	2	2	0	0	1	0	1	0	0	1	1	0	0	0
Inv		0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
Inv	vasive Meningococcal Disease (IMD), Conf															
	vasive Meningococcal Disease (IMD), Prob	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	vasive Pneumococcal Disease (IPD)	4	10	11	2	4	4	2	4	0	0	2	6	0	0	1
	egionellosis	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0
IPE	leningitis, Bacterial (other than Hib, IMD or PD)	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
Me	leningitis, Viral	0	2	3	0	2	2	0	0	0	0	0	0	0	0	1
No	ontuberculosis Mycobacterial Disease	0	7	2	0	3	1	0	2	0	0	2	1	0	0	0
Se	evere Respiratory Illness, unknown origin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tul	uberculosis, non-respiratory	0	2	3	0	1	1	0	0	0	0	0	1	0	1	1
Tul	uberculosis, respiratory	0	5	9	0	0	2	0	0	0	0	1	1	0	4	6
No	hlamydia	63	869	801	45	549	500	4	66	61	8	91	106	6	163	134
Fransmitted and	onorrhoea	6	62	41	5	54	38	0	4	0	1	3	1	0	1	2
bioodborne	epatitis C	6	125	104	4	92	75	1	12	7	1	20	20	0	1	2
	IV Infection	1	8	6	1	8	6	0	0	0	0	0	0	0	0	0
	yphilis, infectious	1	24	9	1	23	5	0	0	1	0	1	3	0	0	0
-	yphilis, non-infectious	0	5	3	0	4	2	0	0	0	0	1	0	0	0	1
la stankanı a 0	yme disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Zoonotic	lalaria	0	3	1	0	2	0	0	1	0	0	0	1	0	0	0
1364363	Fever	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
							-		-			-	-			0
	abies	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	oxoplasmosis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	richinellosis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	/est Nile Virus Infection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preventable	hickenpox	2	104	159	2	60	83	0	29	60	0	8	10	0	7	6
Co	ongenital Rubella Syndrome	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
He	epatitis B	1	13	25	1	8	11	0	2	5	0	0	1	0	3	8
Inv	vasive Haemophilus Influenza type B (Hib)	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0
Me		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Mu	leasles		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pe	,	0														
Ru	leasles	1	10	20	1	10	14	0	0	0	0	0	0	0	0	6
Tel	leasles		<b>10</b>	<b>20</b>	<b>1</b>	<b>10</b>	<b>14</b>	0	0	0	0	0	0	0	0	<b>6</b>
Source: Communicalble Dis	leasles lumps ertussis	1														
Disclaimer: Data are subjec Note: Prior to January 2011	leasles lumps ertussis ubella	<b>1</b> 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

#### References

- 1. Public Health Agency of Canada. (2014). *Clostridium difficile*. Retrieved April 01, 2015, from <u>http://www.phac-aspc.gc.ca/id-mi/cdiff-eng.php</u>
- 2. Oake N, Taljaard M, Walraven CV et al. (2010). The Effect of Hospital-Acquired Clostridium difficile Infection on In-Hospital Mortality. Arch Interna Med, 170(20), 1804-1810.
- 3. Public Health Agency of Canada. (January 2015). Antimicrobial resistant organisms (AROs) Surveillance: Summary Report for Data from January 1, 2009 to June 30, 2014.
- 4. Canadian Patient Safety Institute. Ventilator-associated pneumonia. Retrieved April 13, 2015, from http://www.saferhealthcarenow.ca/EN/Interventions/VAP/Pages/default.aspx
- Centers for Disease Control. (2012). Central line-associated bloodstream infection (CLABSI). Retrieved April 14, 2015, from <u>http://www.cdc.gov/HAI/bsi/bsi.html</u>
- 6. Tambyah P, & Oon J. (2012). Catheter-associated urinary tract infection. Current Opinion in Infectious Diseases, 25(4), 365-370.
- Hooton TM, Bradley SF, Cardenas DD et al. (2010). Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clinical Infectious Diseases, 50(5), 625-663.